1
|
Nicolai N, Nazzani S, Tesone A, Macchi A, Piva L, Salvioni R, Stagni S, Torelli T, Agostini E, Celso F, Giannatempo P, Procopio G, Avuzzi B, Lanocita R, Cattaneo L, Catanzaro M, Biasoni D. Retroperitoneal lymph-node dissection (RPLND) as upfront management in stage II germ-cell tumours: evaluation of safety and efficacy. TUMORI JOURNAL 2022:3008916221112697. [PMID: 35915559 PMCID: PMC10363949 DOI: 10.1177/03008916221112697] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
INTRODUCTION Patients with stage II germ-cell tumours (GCT) usually undergo radiotherapy (seminoma only) or chemotherapy. Both strategies display a recognised risk of long-term side effects. We evaluated retroperitoneal lymph node dissection (RPLND) as exclusive treatment in stage II GCT. METHODS Between 2008 and 2019 included, 66 selected stage II GCT patients underwent primary open (O-) or laparoscopic (L-)RPLND. Type of procedure and extent of dissection, operative time, node rescue, hospital stay, complications (according to Clavien-Dindo), administration of chemotherapy, relapse and site of relapse were evaluated. RESULTS Five patients had pure testicular seminoma. Nineteen (28.8%) had raised markers prior to RPLND; 48 (72.7%), 16 (24.2%) and two (3.0%) were stage IIA, IIB and IIC, respectively. O-RPLND and unilateral L-RPLND were 36 and 30 respectively. Six stage II A patients (12.5%) had negative nodes. Four patients underwent immediate adjuvant chemotherapy. One patient was lost at follow-up. After a median follow-up of 29 months, 48 (77.4%) of the 62 patients undergoing RPLND alone remained recurrence-free; one patient had an in-field recurrence following a bilateral dissection. According to procedure, number of rescued nodes (O-RPLND: 25. IQR 21-31; L-RPLND: 20, IQR 15-26; p: 0.001), hospital stay (L-RPLND: 3 days, IQR 3-4; O-RPLND: 6 days, IQR 5-8; p: .001) and grade ≥2 complications (L-RPLND 7%, O-RPLND 22%; p: 0.1) were the only significant differences. CONCLUSION Primary RPLND is safe in stage II GCT, including seminoma, and may warrant a cure rate greater than 70%. When feasible, L-RPLND may be as effective as O-RPLND with better tolerability.
Collapse
Affiliation(s)
- Nicola Nicolai
- Testis Surgery Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.,Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | | | - Antonio Tesone
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Alberto Macchi
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Luigi Piva
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Roberto Salvioni
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Silvia Stagni
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Tullio Torelli
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Edoardo Agostini
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Francesco Celso
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Patrizia Giannatempo
- Medical Oncology Dept, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Giuseppe Procopio
- Medical Oncology Dept, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Barbara Avuzzi
- Radiation Oncology Dept, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Rodolfo Lanocita
- Radiology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Laura Cattaneo
- Pathology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Mario Catanzaro
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| | - Davide Biasoni
- Urology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
| |
Collapse
|
2
|
Abstract
Germ cell tumors are rare neoplasms that affect young males. Nearly 99% of patients with localized stage I disease and nearly 80% of patients with metastatic disease can be cured. Even patients who relapse following chemotherapy can achieve a long-term survival in approximately 30–40% of cases. The main objective in early stages and in good prognosis patients has changed in recent years, and it has become of major importance to reduce treatment-related morbidity without compromising the excellent long-term survival rate. In poor prognosis patients, there is a correlation between the experience of the treating institution and the long-term clinical outcome of the patients, particularly when the most sophisticated therapies are needed. So far, of utmost importance is the information from updated practice guidelines for the diagnosis and treatment of germ cell tumors. The Italian Germ cell cancer Group (IGG) has developed the following clinical recommendations, which identify the current standards in diagnosis and treatment of germ cell tumors in adult males.
Collapse
|
3
|
Hudolin T, Kastelan Z, Knezevic N, Goluza E, Tomas D, Coric M. Correlation between retroperitoneal lymph node size and presence of metastases in nonseminomatous germ cell tumors. Int J Surg Pathol 2011; 20:15-8. [PMID: 22180527 DOI: 10.1177/1066896911431452] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Eighty-five patients had staging laparoscopic retroperitoneal lymph node dissection (L-RPLND) for nonseminomatous germ cell tumors at our institution. The largest lymph node size was measured and presence or absence of metastatic disease was determined. A total of 1139 lymph nodes have been removed and in 27 (31.8%) patients, metastases in one or more lymph nodes were detected. There were 338 (29.7%) hilar, 259 (22.7%) paraaortic, 221 (19.4%) interaortocaval, 171 (15%) paracaval, 133 (11.7%) preaortic and 17 (1.5%) precaval lymph nodes. The total number of lymph nodes with metastases was 74 (6.5%), and 1065 (93.5%) nodes did not have any metastases. The average size of a lymph node with metastases was 1.05 (0.3-3), and without metastases it was 0.55 (0.1-2.5) cm, (p<0.001). If we use > 1 cm size of a lymph node as a "cut-off" value for enlargement and presence of metastases, 60% of metastatic lymph nodes would be missed since they were all ≤ 1 cm. Our results have shown that decreasing size of lymph nodes which are considered positive from > 1 cm to 0.7 -0.8 cm can be recommended, with specificity and sensitivity equal 70%.
Collapse
Affiliation(s)
- Tvrtko Hudolin
- Department of Urology, KBC Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia.
| | | | | | | | | | | |
Collapse
|
4
|
Oliver RTD, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay J, Robinson A, Neal DE, Williams M. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004; 63:556-61. [PMID: 15028457 DOI: 10.1016/j.urology.2003.10.023] [Citation(s) in RCA: 63] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2002] [Accepted: 10/07/2003] [Indexed: 10/26/2022]
Abstract
OBJECTIVES To study survival and late events after adjuvant chemotherapy in Stage 1 nonseminoma. METHODS From 1978 to 1986, all patients had surveillance. From 1986, adjuvant chemotherapy (initially a 3-day regimen of etoposide, bleomycin, and cisplatin, but, more recently, bleomycin, Oncovin, and cisplatin) was offered to patients at a high risk of relapse (greater than 30%). RESULTS A total of 382 patients with Stage 1 nonseminoma treated between 1978 and 2000 were reviewed. Of the 234 patients treated by surveillance, 71 (30%) had relapses (5 after 2 years), 6 died (2.6%) of germ cell cancer, and 3 developed second primary testicular cancer. Of the 148 men treated with adjuvant chemotherapy, 6 (4%) had relapses and 2 (1.4%) died of chemoresistant cancer. After one course of etoposide, bleomycin, and cisplatin, 3 (6.5%) of 46 developed a relapse; after two courses, 1 (3.6%) of 28 did so; and after bleomycin, Oncovin, and cisplatin every 10 days x2, 2 (2.7%) of 74 patients did so. Of the high-risk patients who were offered adjuvant treatment, 24% declined. As a consequence, the relapse rate of the surveillance patients only fell from 36% to 27% after the introduction of adjuvant therapy, although for the total cohort treated in the adjuvant era, the relapse rate was 16%. CONCLUSIONS Adjuvant chemotherapy is more effective than retroperitoneal lymph node dissection for reducing the relapse risk in high-risk Stage 1 nonseminoma. However, given the uncertainty about the incidence of postchemotherapy late events, surveillance and retroperitoneal lymph node dissection remain justified alternatives. With positron emission tomography and laparoscopy showing increasing promise in these cases, quality-of-life studies and greater patient involvement in treatment selection are needed.
Collapse
Affiliation(s)
- R T D Oliver
- Department of Medical Oncology, Barts and The London Hospitals, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Schneider DT, Calaminus G, Koch S, Teske C, Schmidt P, Haas RJ, Harms D, Göbel U. Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. Pediatr Blood Cancer 2004; 42:169-75. [PMID: 14752882 DOI: 10.1002/pbc.10321] [Citation(s) in RCA: 110] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
BACKGROUND Germ cell tumors (GCTs) constitute a heterogeneous group of tumors that significantly vary with respect to their clinical presentation and biology. The objective of this analysis was to analyze a large population-based pediatric cohort of GCTs and to evaluate the parameters age, sex, site of the tumor, histology, and potential correlations between these parameters. PROCEDURE Between 1981 and 2000, 1,442 patients were prospectively enrolled onto the German protocols for testicular and non-testicular GCTs. Tumors were histologically classified according to the WHO. RESULTS We observed a bimodal age distribution with a first peak during infancy and a second after the onset of puberty. At birth, almost all tumors were teratomas, sometimes with microfoci of yolk sac tumor, which on the other hand, was the predominant histology during childhood. After the onset of puberty, germinomatous GCTs represented the most frequent histological subtype, and malignant non-germinomatous GCTs often presented as mixed tumors with choriocarcinoma and embryonal carcinoma components. During infancy, non-gonadal GCTs accounted for the majority of GCTs, while after the onset of puberty, gonadal GCTs predominated. Notably, among non-gonadal GCTs, there was a female predominance during childhood and a strong male predominance during adolescence. CONCLUSIONS Two separate groups of GCTs with distinct clinical features relevant for differential diagnosis and the diagnostic assessment can be distinguished. This observation correlates with genetic studies that reveal different genetic changes in childhood and adolescence GCTs. Further studies are needed to elucidate the molecular mechanisms of germ cell and GCT development that account for the age- and sex-dependent clinical manifestation.
Collapse
Affiliation(s)
- Dominik T Schneider
- Clinic of Pediatric Hematology and Oncology, Heinrich-Heine-University, Medical Center, Duesseldorf, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
6
|
Nicolai N, Miceli R, Artusi R, Piva L, Pizzocaro G, Salvioni R. A Simple Model for Predicting Nodal Metastasis in Patients With Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors Undergoing Retroperitoneal Lymph Node Dissection Only. J Urol 2004; 171:172-6. [PMID: 14665870 DOI: 10.1097/01.ju.0000101513.64777.f2] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE In patients with clinical stage I nonseminomatous germ cell testicular tumor the identification of risk categories for nodal metastases and/or distant metastases could permit selective management. We built 2 models for distinguishing these risk categories. MATERIALS AND METHODS Data on 322 consecutive patients with clinical stage I nonseminomatous germ cell testicular tumor patients treated with retroperitoneal lymphadenectomy (RPLND) alone between 1985 and 1995 were analyzed. The interval between orchiectomy and RPLND, vascular invasion (VI), pT stage, percent embryonal carcinoma (ECa) and teratoma in the primary tumor were considered clinically relevant for their association with nodal or distant metastases. Two logistic models were constructed. Model 1 was meant to discriminate 2 patient categories, namely those with and without nodal metastases at RPLND. Model 2 was meant to discriminate 3 patient categories, namely those without any metastases, with nodal metastases only and with distant metastases independent of retroperitoneal metastases. The models were based on these above variables, which were inserted as categorical and then processed through a backward selection procedure. RESULTS At RPLND nodal metastases were found in 60 patients (18.6%). During followup distant metastases were observed in 43 patients (13.4%) and retroperitoneal recurrences were noted in 6 (1.9%). Of all recurrences 93.8% were within 2 years since RPLND. RPLND had a high curative rate since 73% of all pN+ cases were cured by surgery alone. The final logistic model 1, including percent ECa and VI, was reassessed in 202 patients with available data. Absent VI and ECa 90% or greater identified a category of 110 patients at low risk for nodal metastasis (14%), while VI and/or ECa greater than 90% identified a category of 92 at higher risk (35%). The identified categories were also related to distant metastases, which occurred in 9.3% of low risk and in 23.1% of high risk cases. Model 2 was not clinically suitable because it did not allow us to distinguish patients at risk for nodal metastases only from those at risk for distant metastases. CONCLUSIONS Simplicity is the main advantage of model 1 since only 2 well-known prognostic parameters are involved. Although the model must be validated in an independent case series, the identification of a low risk category with few expected nodal metastases could permit us to replace traditional RPLND with a less invasive staging procedure.
Collapse
Affiliation(s)
- Nicola Nicolai
- Urology Unit, Department of Surgery, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | |
Collapse
|
7
|
Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell Tumors. J Urol 1996. [DOI: 10.1097/00005392-199602000-00046] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
8
|
Albers P, Ulbright TM, Albers J, Miller GA, Orazi A, Crabtree WN, Baniel J, Reister T, Sidner RA, Foster RS, Donohue JP. Tumor Proliferative Activity is Predictive of Pathological Stage in Clinical Stage a Nonseminomatous Testicular Germ Cell Tumors. J Urol 1996. [DOI: 10.1016/s0022-5347(01)66454-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- Peter Albers
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Thomas M. Ulbright
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Jutta Albers
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Greg A. Miller
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Attilio Orazi
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - William N. Crabtree
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Jack Baniel
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Terry Reister
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Richard A. Sidner
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - Richard S. Foster
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| | - John P. Donohue
- Departments of Urology, Pathology and Biostatistics, Indiana University Medical Center, and Laboratory for Diagnostic and Analytic Cytometry, Indianapolis, Indiana
| |
Collapse
|
9
|
Improved Accuracy of Computerized Tomography Based Clinical Staging in Low Stage Nonseminomatous Germ Cell Cancer Using Size Criteria of Retroperitoneal Lymph Nodes. J Urol 1995. [DOI: 10.1097/00005392-199511000-00049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Leibovitch I, Foster RS, Kopecky KK, Donohue JP. Improved Accuracy of Computerized Tomography Based Clinical Staging in Low Stage Nonseminomatous Germ Cell Cancer Using Size Criteria of Retroperitoneal Lymph Nodes. J Urol 1995. [DOI: 10.1016/s0022-5347(01)66778-8] [Citation(s) in RCA: 75] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Ilan Leibovitch
- Departments of Urology and Radiology, Indiana University Medical Center, Indianapolis, Indiana
| | - Richard S. Foster
- Departments of Urology and Radiology, Indiana University Medical Center, Indianapolis, Indiana
| | - Kenyon K. Kopecky
- Departments of Urology and Radiology, Indiana University Medical Center, Indianapolis, Indiana
| | - John P. Donohue
- Departments of Urology and Radiology, Indiana University Medical Center, Indianapolis, Indiana
| |
Collapse
|
11
|
de Riese C, Crabtree WN, de Riese W, Jones JA, Pastor J, Haupt G, Foster RS, Donohue JP, Senge T. Impact of the preparation technique on DNA content measured by image analysis in early stage human testis cancer. Int Urol Nephrol 1995; 27:603-13. [PMID: 8775046 DOI: 10.1007/bf02564748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Current clinical staging which includes serum tumour markers and imaging techniques fails to identify 30-40% of clinical stage I nonseminomatous germ cell testicular tumour (NSGCT) patients who have occult metastatic disease at time of orchiectomy and who will, therefore, develop clinically evident metastases, usually within two years of follow-up. Therefore, there is a real clinical need to evaluate new biological parameters of the primary tumour which might be useful as predictors for occult metastatic disease. Some investigators have described that DNA content measured by image cytometry is of prognostic value in early stage NSGCT to detect patients at risk for occult metastatic disease. However, optimal preparatory techniques are mandatory in establishing new tumour biological markers in order to obtain reliable and reproducible results. This study has analyzed the impact of the sedimentation technique in comparison to the cytocentrifugation technique on DNA measurement in early stage NSGCT obtained by image cytometry. Different tissue blocks of formalin fixed, paraffin embedded primary testicular tumours (NSGCT) of 50 clinical stage I patients, who underwent retroperitoneal lymph node dissection between 1985 and 1989, were analyzed. Thirty (60%) patients had histologically proven lymph node involvement (pathological stage B), whereas 20 (40%) patients (pathological stage A) had neither lymph node metastases nor tumour recurrence during follow-up. The samples were prepared according to a modified Hedley technique: Individual tissue digestion times were monitored closely to avoid overdigestion. The times varied from 30 to 60 min depending on the constituents of the tissue section. Prolonged digestion times did not correlate with poor quality of the preparations and brief digestion times did not always yield optimal specimens. The impact of two different techniques (cytocentrifugation and gravity sedimentation) on the Feulgen staining results were compared. Cytocentrifuged samples consistently provided larger and paler nuclei with less well defined borders compared to slides from the same cell suspension processed by the sedimentation technique. Nuclei from pathologic stage II samples were more vulnerable to cytocentrifuge alteration than those of stage I. According to the results obtained in this study, the sedimentation slide preparation technique should be preferred for DNA ICM in NSGCT, and possibly in other human malignancies as well.
Collapse
Affiliation(s)
- C de Riese
- Department of Urology, Indiana University School of Medicine, Indianapolis, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Nicolai N, Pizzocaro G. A Surveillance Study of Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: 10-Year Followup. J Urol 1995. [DOI: 10.1016/s0022-5347(01)66972-6] [Citation(s) in RCA: 85] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Nicola Nicolai
- Division of Urology, Istituto Nazionale Tumori, Milan, Italy
| | | |
Collapse
|
13
|
Abstract
BACKGROUND Two similarly effective treatment options exist for managing clinical low volume Stage II nonseminomatous germ cell testis tumors (NSGCT). Primary retroperitoneal lymph node dissection (RPLND) (with immediate adjuvant chemotherapy or chemotherapy at relapse) and primary chemotherapy have resulted in similar survival rates in large series. Because the chance for cure is similar with either approach, the cost and morbidity of therapy should be considered important discriminating factors in deciding which option to pursue for an individual patient. The purpose of this study was to undertake a cost/benefit and risk/benefit analysis of these two options using data and costs from the Indiana University experience. METHODS The overall direct costs for 100 patients undergoing primary RPLND were compared with the total direct costs of 100 patients receiving primary chemotherapy for low volume Stage II disease, including the costs of adjuvant chemotherapy, salvage chemotherapy in relapsing patients, and routine follow-up for a 5-year period. In addition, the two treatment options were analyzed relative to survival, late relapse, acute and chronic toxicity, (including fertility), and perioperative morbidity. RESULTS In this analysis, the overall 5-year costs of RPLND were significantly less than the costs of primary chemotherapy. The two options did not differ significantly in terms of survival or quality of life. Patients receiving RPLND were found to have an advantage also in terms of fertility, toxicity, and late relapse. CONCLUSIONS Treatment decisions for patients with clinical low volume Stage II NSGCT may be based on cost/benefit and risk/benefit considerations, including relative toxicity, long term cure rate, and individual patient preference. Patient compliance with follow-up, the specific expertise of the physicians, and the availability of specialized therapeutic care ultimately may influence such decisions.
Collapse
Affiliation(s)
- J Baniel
- Department of Urology, Indiana University Medical Center, Indianapolis, USA
| | | | | | | |
Collapse
|
14
|
|
15
|
Sosnowski M, Jeromin L, Płuzańska A. Is modified retroperitoneal lymph node dissection (MRLND) still feasible in the treatment of patients with clinical stage I non-seminomatous testicular cancer? Int Urol Nephrol 1994; 26:471-7. [PMID: 7528180 DOI: 10.1007/bf02768020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The results of treatment by means of modified RLND in 52 patients with clinical stage I non-seminomatous testicular cancer are presented. Retroperitoneal lymph node metastases were found in 15 patients (28.8%) with clinical stage I (CS-I) diagnosed prior to surgery. They received chemotherapy according to PVB schedule. Ejaculation disturbances persisted in 4 patients (7.7%). Relapses occurred in 4 patients (7.7%) from the group without lymph node metastases, and complete remission occurred after adjuvant PVB chemotherapy. All patients are still alive. Among the analysed factors which might favour development of metastases, only neoplastic invasion of the blood vessels of the primary tumour was statistically significant. In the authors' opinion MRLND may still be used as a diagnostic and therapeutic method in clinical stage I non-seminomatous testicular cancer besides "watch policy" or primary chemotherapy.
Collapse
Affiliation(s)
- M Sosnowski
- Department of Urology, Medical University of Lódz, Poland
| | | | | |
Collapse
|
16
|
de Riese WT, Albers P, Walker EB, Ulbright TM, Crabtree WN, Reister T, Foster RS, Donohue JP. Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. Cancer 1994; 74:1335-41. [PMID: 8055457 DOI: 10.1002/1097-0142(19940815)74:4<1335::aid-cncr2820740425>3.0.co;2-t] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Thirty percent of patients presenting with clinical stage A nonseminomatous testicular germ cell tumors in fact have pathologic stage B disease. This pilot study was performed to determine whether DNA content and cell cycle analysis by flow cytometry and single-cell cytophotometry can improve clinical staging in these patients. METHODS The orchiectomy specimens of 102 patients with clinical stage A disease were analyzed retrospectively using histopathologic classification, flow cytometry, and single-cell cytophotometry. All patients had undergone retroperitoneal lymph node dissection. RESULTS The multivariate analysis in this group of patients resulted in the following model: If the primary tumor consisted of 100% embryonal carcinoma, the patient was classified as high risk for retroperitoneal metastasis. If the patient was found to have less than 100% embryonal carcinoma in the primary tumor, the percent of aneuploid tumor cells in S-phase as identified by flow cytometry was most predictive for pathologic stage. Using this approach, 91% of all patients with pathologic stage B, and 77% of the patients with pathologic stage A were correctly classified; test efficiency was 82%. CONCLUSIONS These results demonstrate an improvement in clinical staging in this group of patients. This paradigm, developed from retrospective analysis, will be tested prospectively in consecutive patients to determine if it is clinically useful.
Collapse
Affiliation(s)
- W T de Riese
- Department of Urology, Indiana University Medical Center, Indianapolis 46202
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Fernandez EB, Colon E, McLeod DG, Moul JW. Efficacy of radiographic chest imaging in patients with testicular cancer. Urology 1994; 44:243-8; discussion 248-9. [PMID: 8048200 DOI: 10.1016/s0090-4295(94)80139-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
OBJECTIVE To determine the efficacy of computed tomography of the chest (CTC) and plain radiograph (CXR) in the initial staging process of testicular germ cell tumors. METHODS The medical records of 362 patients with testicular germ cell tumor treated at our center between January 1980 and August 1993 were reviewed with particular attention to initial chest screening studies. Two hundred one patients had both CXR and CTC, 24 CXR alone, and 20 CTC alone during initial staging. One hundred seventeen patients were excluded from analyses because of undergoing whole lung tomography (92), unknown staging (19), or inadequate follow-up (6). Analysis included findings based on abdominal staging results using computed tomography of the abdomen (CTA). RESULTS Of the 201 patients who had both CTC and CXR, 117 (58.2%) had nonseminomas (NSGCT) and 84 (41.8%) had seminomas (SEM). Among the patients with NSGCT, 21 (17.9%) had chest metastasis, 16 (76.2%) of which were detected by CXR. The 5 that were missed on CXR had significant retroperitoneal disease documented by CTA and the knowledge of chest metastases potentially altered therapy in 2 patients. Only 2 of 84 (2.4%) patients with SEM had metastatic chest disease and both were identified by CXR. False-positive CTC following negative CXR resulted in costly and sometimes invasive additional procedures in 10 patients with NSGCT and 6 with SEM. None of the CXR-only patients had adverse consequences from the solitary study (at least 1 year follow-up). The CTC-only patients could have undergone CXR only and had similar outcome. CONCLUSIONS CXR alone is preferable for initial chest staging in all patients with SEM and in patients with NSGCT with negative findings on CTA. CTC remains of slight benefit for patients with clinical Stage II and greater NSGCT and to evaluate further suspicious CXR findings in any patient, although it appears not to be necessary in patients who have clinical Stage I disease determined by CTA. These findings have important cost-saving implications.
Collapse
Affiliation(s)
- E B Fernandez
- Department of Surgery, Walter Reed Army Medical Center, Washington, DC
| | | | | | | |
Collapse
|
18
|
de Riese W, Walker EB, de Riese C, Ulbright TM, Crabtree WN, Messemer J, Jones JA, Hinkel A, Foster RS, Donohue JP. Quantitative DNA measurement by flow cytometry and image analysis of human nonseminomatous germ cell testicular tumors. UROLOGICAL RESEARCH 1994; 22:213-20. [PMID: 7871632 DOI: 10.1007/bf00541895] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Current clinical staging, which includes the use of serum tumor markers and imaging techniques, fails to identify the 30-40% of clinical stage I (CS I) nonseminomatous germ cell testicular tumor (NSGCT) patients who have occult metastatic disease. Therefore, there is a real clinical need to evaluate new biological parameters of the primary tumor that might be useful as predictors of occult metastatic disease. This study was undertaken to compare quantitative DNA measurements by flow cytometry and image analysis in CS I NSGCT, and to analyze the relevance of these parameters for predicting occult lymph node involvement. Different blocks of formalin-fixed, paraffin-embedded NSGCTs of 62 CS I patients who underwent retroperitoneal lymph node dissection between 1985 and 1989 were prepared according to the Hedley technique, and analyzed by quantitative cytometry. Thirty-six (58.1%) patients had histologically proven lymph node involvement (pathological stage II), whereas 26 (41.9%) patients (pathological stage I) had neither lymph node metastases according to retroperitoneal lymph node dissection (RPLND) specimens nor tumor recurrence during follow-up. Concordant results were found in 76.5% of the samples by both cytometric techniques. For flow cytometry, the percentages of aneuploid cells in the S- and the G2M + S-phase were the most robust predictive parameters for lymph node involvement, whereas for image analysis the 5c exceeding rate (5cER) had the most predictive significance. Based on the experience obtained in this study, both cytometric techniques provide additional information on tumor aggressiveness that might be useful in therapeutic selection of early stage NSGCT patients for either RPLND or surveillance only.
Collapse
Affiliation(s)
- W de Riese
- Urologie, Marienhospital, Ruhruniversität Bochum, Herne, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
A retrospective survival analysis was performed on 287 patients treated with chemotherapy following orchidectomy for stage II testicular non-seminoma between 1982 and 1986 at a number of centres in the United Kingdom and 1 centre in Norway. A total of 80 patients had lymphadenectomy for a residual mass after chemotherapy. In 17 of these cases the histology was undifferentiated malignancy, in 44 it was differentiated teratoma, in 18 there was necrosis only and in 1 case histology was unknown. The overall survival in 47 patients with initial stage IIA disease (nodes measuring < 2 cm in transverse diameter) was 98% [95% confidence interval (CI), 96%-100%] at 3 years. In 175 patients with stage IIB disease (nodal diameter, 2-5 cm) the 3-year survival was 96% (95% CI, 93%-99%) and in 65 patients with stage IIC disease (nodal diameter, > 5 cm) it was 84% (95% CI, 75%-93%). In stage IIA and stage IIB disease this approach leads to survival equivalent to that obtained with the approach of initial retroperitoneal lymph-node dissection.
Collapse
Affiliation(s)
- A Horwich
- Urological Oncology Unit, Royal Marsden Hospital, Sutton, Surrey, UK
| | | |
Collapse
|
20
|
De Riese WT, De Riese C, Ulbright TM, Walker EB, Messemer J, Jones JA, Reister T, Albers P, Allhoff EP, Foster RS. Flow-cytometric and quantitative histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical-stage-I non-seminomatous testicular germ-cell tumors. Int J Cancer 1994; 57:628-33. [PMID: 8194868 DOI: 10.1002/ijc.2910570503] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Our study was performed to clarify whether the combination of DNA flow-cytometric and quantitative histopathological parameters improves the prediction of occult metastatic disease in clinical stage-I non-seminomatous testicular germ-cell tumors (NSGCT). We used archival paraffin primary-tumor tissue of 67 clinical stage-I NSGCT patients who had undergone retroperitoneal lymph-node dissection (RPLND). According to the RPLND specimens, 24 patients were at pathological stage I and 43 at pathological stage II. Archival blocks were redissected for histological re-evaluation. In addition, 50 microns sections were prepared according to the Hedley technique in order to obtain nuclear suspensions which were processed for flow cytometry (FC). In univariate analysis, the percentage of embryonal carcinoma, the percentage of immature teratoma and vascular invasion were the most accurate predictive histopathological parameters. The percentage of aneuploid cells in S-phase was the best predictive FC parameter. In multivariate analysis, the percentage of embryonal carcinoma and the S-phase fraction of aneuploid cells were the only independent markers for occult metastatic disease. According to this statistical approach, 91.0% of pathological stage-I and stage-II cases were correctly classified. Sensitivity was 95.3% and specificity was 83.3%. Using histopathological criteria alone, only 56.7% NSGCT patients were correctly classified.
Collapse
Affiliation(s)
- W T De Riese
- Department of Urology, Indiana University, Indianapolis
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Horwich A, Norman A, Fisher C, Hendry WF, Nicholls J, Dearnaley DP. Primary chemotherapy for stage II nonseminomatous germ cell tumors of the testis. J Urol 1994; 151:72-7; discussion 77-8. [PMID: 8254836 DOI: 10.1016/s0022-5347(17)34874-7] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Between 1979 and 1989, 122 patients with clinical stage II testicular nonseminoma were treated with primary platinum-based combination chemotherapy following orchiectomy. Of the patients 58 had Royal Marsden Hospital stage IIA (nodes less than 2 cm. in diameter) and the other 64 had stage IIB (nodes 2 to 5 cm. diameter) disease. With a median followup after chemotherapy of 5.5 years, 118 patients (97%) were disease-free. Two patients died of progressive germ cell tumors, 1 of bleomycin toxicity and 1 of coincidental disease. The 5-year actuarial survival probability was 95% (95% confidence intervals 91 to 99%) and the 5-year failure-free survival probability was 92% (95% confidence intervals 88 to 97%). Tumor substage was not predictive of relapse but did indicate the probability of lymphadenectomy for a post-chemotherapy residual mass since this was performed in 17% of the patients with stage IIA disease and 39% with stage IIB disease (p < 0.05). Resected specimens contained mature teratoma (29), necrosis alone (5) or embryonal carcinoma (1). We conclude that for these clinical stages primary chemotherapy was as effective as primary lymph node dissection and a major operation was avoided in 68% of the cases.
Collapse
Affiliation(s)
- A Horwich
- Department of Histopathology and Computing, Royal Marsden Hospital, Surrey, United Kingdom
| | | | | | | | | | | |
Collapse
|